Diagnostic Criteria and Prognosis of Pancreatic Lymphoma

This entry looks at pancreatic lymphoma, or primary pancreatic lymphoma (PPL), one of the subtypes of lymphoma. 'Lymphoma' is an umbrella term that loosely refers to several dozen independent categorical types and subtypes of cancers of the lymphatic system.

What is Pancreatic Lymphoma?

Primary pancreatic lymphoma is a cancer of the lymphocytes that originates as a pancreatic mass, and is not the result of an invasion from nearby lymph nodes. It is important that a pancreatic mass be quickly identified as either a lymphoma or an adenocarcinoma, since each is approached differently from a treatment perspective and the latter is far more serious.

Primary pancreatic lymphoma appears to be much more common in men than in women, but it is by any standard a very rare disease. It represents about 1 percent of all pancreatic masses, and about 1 percent of extra-nodal non-Hodgkin's lymphomas, making for a rather small number indeed. However, secondary pancreatic lymphoma, in which lymphoma spreads to the pancreas, is a fairly common organ for extra-nodal involvement as a secondary site.

Diagnostic Criteria for Pancreatic Lymphoma

There are three criteria in order to diagnose PPL. They are:

  1. No lymph node enlargement of superficial or mediastinal lymph nodes;
  2. A normal leukocyte count in the peripheral blood;
  3. No involvement of the liver or spleen.

Symptoms of Pancreatic Lymphoma

Signs and symptoms of PPL are generally non-specific, meaning they could indicate many things in addition to PPL. A person could experience abdominal pain of variable severity and small bowel obstruction, along with the constellation of B symptoms, including loss of appetite, unexplained weight loss, fatigue, and night sweats.

Furthermore, patients with pancreatic lymphoma tend to have normal white blood cell counts. A trademark of the disease from the laboratory perspective is elevated LDH.

Treatment and Prognosis for Pancreatic Lymphoma

Treatment for PPL can include surgery (surgical resection), combination chemotherapy, or sometimes radiation along with chemotherapy. Studies suggest that when treated with chemotherapy, prognosis for PPL is very good.

Sources

Photo: Pixabay

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap